(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.39%) $79.30
(-0.46%) $2.18
(-0.23%) $2 317.00
(-0.08%) $27.58
(0.31%) $987.70
(0.06%) $0.931
(0.15%) $10.91
(0.03%) $0.800
(0.01%) $91.75
-3.04% $ 1.925
Live Chart Being Loaded With Signals
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada...
Stats | |
---|---|
Dzisiejszy wolumen | 1 617.00 |
Średni wolumen | 17 011.00 |
Kapitalizacja rynkowa | 36.49M |
EPS | $0 ( 2024-04-03 ) |
Następna data zysków | ( $0 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.800 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Warma Neil K | Buy | 200 000 | Option (right to buy) |
2023-12-04 | Sclar Jeremy M. | Buy | 150 000 | Series 2 Preferred Shares, no par value |
2022-10-11 | Sclar Jeremy M. | Buy | 26 217 | Warrants to Purchase Common Shares, no par value |
2023-12-04 | Sclar Jeremy M. | Sell | 150 000 | Series 1 Preferred Shares, no par value |
2023-12-25 | Title 19 Promis | Sell | 0 | Common Shares, no par value |
INSIDER POWER |
---|
-43.18 |
Last 83 transactions |
Buy: 847 135 | Sell: 2 093 488 |
ProMIS Neurosciences, Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
ProMIS Neurosciences, Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-1.070 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-1.070 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-1.700 |
Financial Reports:
No articles found.
ProMIS Neurosciences,
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej